Evidence map›Paper›PMID 39044298›Full record

ArticleMilitary Medical Research2024

Hippocampal PACAP signaling activation triggers a rapid antidepressant response.

Hai-Lou Zhang, Yan Sun, Zhang-Jie Wu, Ying Yin, Rui-Yi Liu, Ji-Chun Zhang, Zhang-Jin Zhang, Suk-Yu Yau, Hao-Xin Wu, Ti-Fei Yuan and 3 more

Abstract read
In one paragraph

Article in Military Medical Research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Molecular medicine reports · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Neuropsychiatric disease and treatment · 2026
    Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. A Comprehensive 4-layeredCurrent pharmaceutical biotechnology · 2025
    Article
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Hai-Lou Zhang *Interdisciplinary Institute for Personalized Medicine in Brain Disorders, Jinan University, Guangzhou, 510632, China.
Yan Sun *Key Laboratory of Integrative Biomedicine for Brain Diseases, School of Chinese Medicine, Nanjing University of Chinese Medicine, Nanjing, 210023, China.
Zhang-Jie WuInterdisciplinary Institute for Personalized Medicine in Brain Disorders, Jinan University, Guangzhou, 510632, China.
Ying YinInterdisciplinary Institute for Personalized Medicine in Brain Disorders, Jinan University, Guangzhou, 510632, China.
Rui-Yi LiuInterdisciplinary Institute for Personalized Medicine in Brain Disorders, Jinan University, Guangzhou, 510632, China.
Ji-Chun ZhangSchool of Medicine, Jinan University, Guangzhou, 510632, China.
Zhang-Jin ZhangSchool of Chinese Medicine, LKS Faculty of Medicine, the University of Hong Kong, Hong Kong, 999077, China.
Suk-Yu YauThe Guangdong-Hongkong-Macau Joint Laboratory of Traditional Chinese Medicine Regulation of Brain-Periphery Homeostasis and Comprehensive Health, Guangzhou, 510632, China.
Hao-Xin WuKey Laboratory of Integrative Biomedicine for Brain Diseases, School of Chinese Medicine, Nanjing University of Chinese Medicine, Nanjing, 210023, China.
Ti-Fei YuanShanghai Mental Health Center, Shanghai, 200030, China.
Li ZhangKey Laboratory of Central CNS Regeneration (Ministry of Education), Guangdong-Hong Kong-Macau Institute of CNS Regeneration, Jinan University, Guangzhou, 510632, China.
Miroslav Adzic"Vinča" Institute of Nuclear Sciences, Laboratory of Molecular Biology and Endocrinology 090, University of Belgrade, 11001, Belgrade, Serbia.
Gang ChenInterdisciplinary Institute for Personalized Medicine in Brain Disorders, Jinan University, Guangzhou, 510632, China. chengang@jnu.edu.cn.ORCID 0000-0002-3507-1218

Funding

Guangzhou Key Science and Technology R&D Project 202206010109National Key R&D Program of China 2022YFE0201000National Science Foundation of China 82174002
6 · The paper itself

Abstract

backgroundThe development of ketamine-like rapid antidepressants holds promise for enhancing the therapeutic efficacy of depression, but the underlying cellular and molecular mechanisms remain unclear. Implicated in depression regulation, the neuropeptide pituitary adenylate cyclase-activating polypeptide (PACAP) is investigated here to examine its role in mediating the rapid antidepressant response.

methodsThe onset of antidepressant response was assessed through depression-related behavioral paradigms. The signaling mechanism of PACAP in the hippocampal dentate gyrus (DG) was evaluated by utilizing site-directed gene knockdown, pharmacological interventions, or optogenetic manipulations. Overall, 446 mice were used for behavioral and molecular signaling testing. Mice were divided into control or experimental groups randomly in each experiment, and the experimental manipulations included: chronic paroxetine treatments (4, 9, 14 d) or a single treatment of ketamine; social defeat or lipopolysaccharides-injection induced depression models; different doses of PACAP (0.4, 2, 4 ng/site; microinjected into the hippocampal DG); pharmacological intra-DG interventions (CALM and PACAP6-38); intra-DG viral-mediated PACAP RNAi; and opotogenetics using channelrhodopsins 2 (ChR2) or endoplasmic natronomonas halorhodopsine 3.0 (eNpHR3.0). Behavioral paradigms included novelty suppressed feeding test, tail suspension test, forced swimming test, and sucrose preference test. Western blotting, ELISA, or quantitative real-time PCR (RT-PCR) analysis were used to detect the expressions of proteins/peptides or genes in the hippocampus.

resultsChronic administration of the slow-onset antidepressant paroxetine resulted in an increase in hippocampal PACAP expression, and intra-DG blockade of PACAP attenuated the onset of the antidepressant response. The levels of hippocampal PACAP expression were reduced in both two distinct depression animal models and intra-DG knockdown of PACAP induced depression-like behaviors. Conversely, a single infusion of PACAP into the DG region produced a rapid and sustained antidepressant response in both normal and chronically stressed mice. Optogenetic intra-DG excitation of PACAP-expressing neurons instantly elicited antidepressant responses, while optogenetic inhibition induced depression-like behaviors. The longer optogenetic excitation/inhibition elicited the more sustained antidepressant/depression-like responses. Intra-DG PACAP infusion immediately facilitated the signaling for rapid antidepressant response by inhibiting calcium/calmodulin-dependent protein kinase II (CaMKII)-eukaryotic elongation factor 2 (eEF2) and activating the mammalian target of rapamycin (mTOR). Pre-activation of CaMKII signaling within the DG blunted PACAP-induced rapid antidepressant response as well as eEF2-mTOR-brain-derived neurotrophic factor (BDNF) signaling. Finally, acute ketamine treatment upregulated hippocampal PACAP expression, whereas intra-DG blockade of PACAP signaling attenuated ketamine's rapid antidepressant response.

conclusionsActivation of hippocampal PACAP signaling induces a rapid antidepressant response through the regulation of CaMKII inhibition-governed eEF2-mTOR-BDNF signaling.

Indexed as

DepressionHippocampusPituitary Adenylate Cyclase-Activating PolypeptideSignal TransductionAnimalsAntidepressive AgentsBehavior, AnimalDisease Models, AnimalMaleMiceParoxetineAdcyap1 protein, mouseAntidepressive AgentsParoxetinePituitary Adenylate Cyclase-Activating PolypeptideAntidepressant responseKetamineNovelty suppressed feeding (NSF)OptogeneticPituitary adenylate cyclase-activating polypeptide (PACAP)

Identifiers

PMID39044298
PMCPMC11265467

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.